Less Ads, More Data, More Tools Register for FREE

Pin to quick picksChrysalis Inves Regulatory News (CHRY)

Share Price Information for Chrysalis Inves (CHRY)

Share Price is delayed by 15 minutes
Get Live Data
76.90    0.20 (0.26%)
Bid:
76.80
Ask:
77.00
Spread: 0.20 (0.26%)
Market Cap: £369.87m
CHRY Live PriceLast checked at - London Stock Exchange

Intraday Chrysalis Inves Share Chart

Debt Facility

25 Sep 2024 07:00

RNS Number : 5154F
Chrysalis Investments Limited
25 September 2024
Β 

The information contained in this announcement is restricted and is not for publication, release or distribution in the United States of America, any member state of the European Economic Area (other than to professional investors in Belgium, Denmark, the Republic of Ireland, Luxembourg, the Netherlands, Norway and Sweden), Canada, Australia, Japan or the Republic of South Africa.

Β 

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 which forms part of domestic law in the United Kingdom pursuant to The European Union Withdrawal Act 2018, as amended by The Market Abuse (Amendment) (EU Exit) Regulations 2019.

Β 

Β 

Β 

25 September 2024

Β 

Β 

Chrysalis Investments Limited ("Chrysalis" or the "Company")

Β 

Debt Facility

Β 

Β 

Debt Facility

Β 

Subsequent to recent indications that it was considering options to enhance liquidity and so enable the Company's capital allocation policy ("CAP") to take effect at the earliest opportunity, including potential short-term gearing, the Company is pleased to announce that it has agreed a Β£70 million debt facility with Barclays Bank plc ("Barclays"). In addition to the committed Β£70 million, the facility also includes an uncommitted accordion of Β£15 million.

Β 

The Company will shortly inform Barclays of its intention to draw down the full Β£70 million commitment.

Β 

The agreement has a two-year tenor, which the Investment Adviser believes provides sufficient time for potential further realisations to occur, while falling within the three-year continuation period extension, which was approved by shareholders in March 2024. A market-rate margin plus the daily SONIA rate will be charged on borrowed amounts, with an arrangement fee also payable on the full commitment. The facility is repayable with no cost after one year.

Β 

The quantum of the facility is designed to cover the "buffer" element of the CAP (the "Buffer"), which the Board and Investment Adviser currently believe is appropriately set at approximately Β£50 million. The Buffer is designed to cover working capital and potential follow-on investments.

Β 

When the Buffer requirement is fulfilled by the facility, the Board will be in a position to consider the second pillar of the CAP, namely the return of up to Β£100 million to shareholders, likely through the commencement of share buybacks. The timing of any returns of capital will be dependent on receipt of funds from Barclays, amongst other relevant considerations, and a further announcement on this will be made in due course.

Β 

Given the above, both the Board and the Investment Adviser consider the benefits of the facility will outweigh the costs to the Company.

Β 

The maximum level of gearing in the Company, as measured against NAV and assuming the facility is fully drawn, is modest at approximately 8.1%, based on NAV as of 30 June 2024.

Β 

Liquidity

Β 

The Company's liquidity position as of 23 September 2024 was Β£47.2m, comprising cash of Β£45.3 million and a position in Wise worth Β£1.9 million. Once the Β£70 million drawdown on the facility is received, liquidity would increase to approximately Β£117.2 million, representing approximately 23% of its market capitalisation (as of 23 September 2024).

Β 

Nick Williamson and Richard Watts (Managing Partners of the Investment Adviser) comment:

Β 

"As we have articulated to shareholders in recent months, we believe the addition of a modest amount of debt will allow the Company to accelerate returns to shareholders as realisations occur within the portfolio. With the shares currently trading on a circa 41% discount to NAV and with a strong portfolio, we believe share buybacks could offer a compelling way to accrete NAV per share to the benefit of long-term shareholders.

Β 

We continue to work to maximise the valuations of the portfolio companies and to explore ways to realise this value."

Β 

-ENDS-

Β 

Β 

Β 

Β 

For further information, please contact

Β 

Media

Montfort Communications:

Charlotte McMullen / Imogen Saunders

Β 

Β 

Β 

Β 

Β 

Β 

+44 (0) 7921 881 800

chrysalis@montfort.london

Β 

Β 

Investment Adviser

Chrysalis Investment Partners LLP:

James Simpson

Β 

+44 (0) 20 7871 5343

G10 Capital Limited (AIFM):

+44 (0) 20 7397 5450

Maria Baldwin

Β 

Β 

Β 

Panmure Liberum:

Chris Clarke / Darren Vickers

Β 

+44 (0) 20 3100 2222

Deutsche Numis:

Nathan Brown / Matt Goss

Β 

+44 (0) 20 7260 1000

IQEQ Fund Services (Guernsey) Limited:

Aimee Gontier / Elaine Smeja

+44 (0) 1481 231852

Β 

LEI: 213800F9SQ753JQHSW24

A copy of this announcement will be available on the Company's website at https://www.chrysalisinvestments.co.uk

The information contained in this announcement regarding the Company's investments has been provided by the relevant underlying portfolio company and has not been independently verified by the Company. The information contained herein is unaudited.

This announcement is for information purposes only and is not an offer to invest. All investments are subject to risk. Past performance is no guarantee of future returns. Prospective investors are advised to seek expert legal, financial, tax and other professional advice before making any investment decision. The value of investments may fluctuate. Results achieved in the past are no guarantee of future results. Neither the content of the Company's website, nor the content on any website accessible from hyperlinks on its website for any other website, is incorporated into, or forms part of, this announcement nor, unless previously published by means of a recognised information service, should any such content be relied upon in reaching a decision as to whether or not to acquire, continue to hold, or dispose of, securities in the Company.

The Company is an alternative investment fund ("AIF") for the purposes of the AIFM Directive and as such is required to have an investment manager who is duly authorised to undertake the role of an alternative investment fund manager ("AIFM"). The AIFM appointed is G10 Capital Limited (part of the IQEQ Group).

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Β 
END
Β 
Β 
MSCSEIESLELSEEU
Date   Source Headline
30th May 20227:00 amRNSDirector/PDMR Shareholding
23rd May 20227:00 amRNSQuarterly Net Asset Value and Trading Update
13th May 202211:40 amRNSDirector/PDMR Shareholding
14th Apr 20227:00 amRNSInterim NAV Announcement
17th Mar 202211:34 amRNSHolding(s) in Company
21st Feb 20227:00 amRNSQuarterly NAV Announcement and Trading Update
18th Feb 20222:21 pmRNSPublication of a Supplementary Prospectus
18th Feb 20227:00 amRNSResult of AGM
10th Feb 20224:15 pmRNSDirector/PDMR Shareholding
4th Feb 20224:52 pmRNSCorrection to AGM Resolution No. 11
3rd Feb 20223:19 pmRNSDirector/PDMR Shareholding
1st Feb 20222:06 pmRNSPortfolio Update
1st Feb 20227:00 amRNSNotice of AGM
31st Jan 20224:19 pmRNSHolding(s) in Company
31st Jan 202210:59 amRNSHolding(s) in Company
26th Jan 20227:00 amRNSAnnual Financial Report
16th Dec 202111:24 amRNSHolding(s) in Company
13th Dec 20217:00 amRNSResults of Capital Raise
1st Dec 20217:01 amRNSPrimaryBid Offer
1st Dec 20217:00 amRNSProposed Placing
29th Nov 20217:01 amRNSUpdate on Performance Fee Arrangements
29th Nov 20217:00 amRNSNet Asset Value(s) and Trading Update
18th Oct 20212:39 pmRNSDirector/PDMR Shareholding
18th Oct 20212:36 pmRNSDirector/PDMR Shareholding
11th Oct 20217:00 amRNSDepositary Business Transfer
17th Sep 20211:12 pmRNSHolding(s) in Company
20th Aug 20217:00 amRNSQuarterly NAV Announcement
19th Aug 20217:00 amRNSPortfolio Update
17th Aug 202111:29 amRNSPortfolio Update
5th Aug 20214:33 pmRNSUK Government Engagement
29th Jul 20217:00 amRNSPortfolio Update
7th Jul 202111:58 amRNSPortfolio Update
6th Jul 20217:00 amRNSPortfolio Update
30th Jun 20217:00 amRNSInterim Results to 31 March 2021
29th Jun 20217:00 amRNSPortfolio Update
28th Jun 20217:00 amRNSPortfolio Update
25th Jun 20211:02 pmRNSHolding(s) in Company
24th Jun 20217:00 amRNSPortfolio Update
10th Jun 20212:17 pmRNSPortfolio Update
1st Jun 20212:38 pmRNSPortfolio Update
1st Jun 20217:00 amRNSNAV Update
26th May 20217:00 amRNSNet Asset Value(s)
11th May 20211:20 pmRNSDirector/PDMR Shareholding
6th May 20217:00 amRNSChange of AIFM
1st Apr 20215:44 pmRNSHolding(s) in Company
1st Apr 20214:17 pmRNSHolding(s) in Company
26th Mar 20212:57 pmRNSDirector/PDMR Shareholding
26th Mar 20217:00 amRNSResult of Initial Issue
10th Mar 20217:00 amRNSPlacing Programme, Issue,Revolving Credit Facility
8th Mar 20214:59 pmRNSResults of Extraordinary General Meeting

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.